Physician profile
Niraj M Mehta
NPI 1730186230
$1,627.31
in general payments reported to CMS, 2019-2025
17 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.91 · 2022: $193 · 2023: $269 · 2024: $376 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $366.33 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Corcept Therapeutics | $314.18 | 2024-2025 | Korlym |
| Antares Pharma, INC. | $209.00 | 2025 | Xyosted |
| Dexcom, INC. | $183.89 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Revance Therapeutics, INC. | $104.48 | 2024 | Daxxify |
| Alexion Pharmaceuticals, INC. | $97.31 | 2021-2023 | |
| Exact Sciences Corporation | $83.30 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $50.76 | 2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $39.88 | 2022-2023 | Xarelto |
| Astellas Pharma US INC | $36.57 | 2023-2024 | Veozah |
| Medtronic, INC. | $34.21 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.58 | 2025 | Jardiance |
| Galderma Laboratories, L.P. | $21.10 | 2023 | |
| Abbvie INC. | $18.82 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.74 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14.94 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.